Researchers may have uncovered a new reason behind pediatric cancer development, potentially allowing earlier disease detection in children. A study conducted by scientists at the University of Bergen in Norway revealed that children with pediatric cancer tend to produce autoantibodies targeting several key proteins involved in DNA repair. Remarkably, these antibodies were present years before cancer diagnosis.
The study, published in Frontiers in Immunology on October 14, highlights that while childhood cancer is rare, common types include blood cancers such as leukemia and lymphoma, along with brain, spinal cord, and bone tumors. In contrast, adult cancers more typically involve the lungs, breast, colon, prostate, and skin. This means that the cells where cancers originate often differ between children and adults.
What Are Autoantibodies?
Antibodies help the immune system identify and destroy threats like viruses. Autoantibodies, however, mistakenly attack the body, misidentifying healthy tissue. They inadvertently target the body’s own cells instead of true threats, potentially leading to autoimmune diseases like type 1 diabetes, lupus, Graves’ disease, multiple sclerosis, and rheumatoid arthritis.
The specific cause behind this immune system malfunction is unclear, though it might stem from triggers like infections, environmental toxins, or genetics.
Study Insights
Researchers examined tumor and blood samples from 175 adults and children with sarcoma or acute lymphoblastic leukemia between 2014 and 2017. This research sourced data from the NoSarC Norwegian Sarcoma Study, the Norwegian Childhood Cancer Biobank, and the Oslo University Hospital Cancer Research Biobank.
These samples were measured against healthy individuals, including blood donors and children from the Bergen Growth Study. The findings showed children aged two to 19 with cancer had significantly more IgG class antibodies. These antibodies targeted genes like RAD52, NUMA1, ALKBH7, APBB1, UNG, and MGMT, all crucial for DNA repair.
Ola Myklebost, the study author and a molecular oncology professor at the University of Bergen, explained that while mutated cancer proteins are known to induce autoantibodies, their results were surprising. The study demonstrated these autoantibodies could enter cells, binding to DNA repair proteins outside the nucleus, hindering repair activity. This mechanism elevates the mutation rate, increasing cancer risk. Myklebost noted their detection of these autoantibodies was eight times higher in children later diagnosed with cancer compared to healthy controls.
Dr. Yvonne Saenger, a medicine professor at Stony Brook University uninvolved in the study, emphasized the importance of immune response differences between cancer patients and healthy individuals for immunotherapy applications. She noted further research must determine if these antibodies affect cellular processes or arise due to tumors.
Implications of the Findings
Myklebost suggested this hypothesis could explain cancer onset in children and possibly adults. Confirming causality and understanding the specific autoantibody patterns are necessary steps. If validated, screening children for these antibodies might assess cancer risk, potentially allowing intervention to eliminate or block harmful cells.
Anastassia Serguienko, a study author and senior researcher at the University of Bergen, advocated for future research to focus on the mechanisms and biology of penetrating autoantibodies, which could contribute to numerous human diseases.
Leave a Reply